Holders — by stockHoldings — by fund
Vivo Capital, LLC
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001674712
$1.10B
disclosed book value
47
positions
8.7%
largest position share
Positions, as of 2026-06-30
top 47 of 47 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | TRVITrevi Therapeutics Inc | 5.1M | $95.0M | 8.7% |
| 2 | PRAXPraxis Precision Medicines | 271,116 | $90.8M | 8.3% |
| 3 | ERASErasca Inc | 4.1M | $75.6M | 6.9% |
| 4 | AVBPArrivent BioPharma Inc | 1.7M | $58.4M | 5.3% |
| 5 | ABVXAbivax SA - ADR | 414,899 | $55.3M | 5% |
| 6 | TNGXTango Therapeutics Inc | 1.4M | $43.1M | 3.9% |
| 7 | CRVSCorvus Pharmaceuticals Inc | 2.8M | $41.9M | 3.8% |
| 8 | DRUGBright Minds Biosciences Inc | 557,172 | $39.1M | 3.6% |
| 9 | Sinovac Biotech Ltd. | 5.9M | $38.2M | 3.5% |
| 10 | TENXTenax Therapeutics Inc | 2.5M | $36.4M | 3.3% |
| 11 | ACRSAclaris Therapeutics, Inc. | 6.7M | $35.4M | 3.2% |
| 12 | DYNDyne Therapeutics Inc | 1.6M | $34.6M | 3.2% |
| 13 | DNTHDianthus Therapeutics Inc | 353,998 | $34.5M | 3.2% |
| 14 | ANROAlto Neuroscience Inc | 1.2M | $31.9M | 2.9% |
| 15 | DBVTDBV Technologies SA | 1.8M | $30.3M | 2.8% |
| 16 | SABSSAB Biotherapeutics Inc | 7.3M | $28.5M | 2.6% |
| 17 | MLTXMoonlake Immunotherapeutics | 1.4M | $27.3M | 2.5% |
| 18 | LBRXLB Pharmaceuticals Inc | 800,000 | $26.0M | 2.4% |
| 19 | NERVMinerva Neurosciences Inc | 4.3M | $24.0M | 2.2% |
| 20 | DSGNDesign Therapeutics Inc | 1.6M | $23.3M | 2.1% |
| 21 | ORICOric Pharmaceuticals Inc | 1.8M | $20.0M | 1.8% |
| 22 | CAMPCAMP4 Therapeutics Corporation | 4.2M | $18.6M | 1.7% |
| 23 | FTHFaeth Therapeutics Inc | 722,020 | $18.1M | 1.6% |
| 24 | ACHVAchieve Life Sciences Inc. | 2.8M | $18.0M | 1.6% |
| 25 | CMPXCompass Therapeutics Inc | 7.8M | $17.0M | 1.6% |
| 26 | ANTXAN2 Therapeutics Inc | 3.2M | $15.3M | 1.4% |
| 27 | EDITEditas Medicine Inc | 3.6M | $11.5M | 1.1% |
| 28 | GERNGeron Corp | 8.7M | $11.1M | 1% |
| 29 | ODTXOdyssey Therapeutics Inc | 575,000 | $10.8M | 1% |
| 30 | EPRXEupraxia Pharmaceuticals Inc | 1.4M | $8.9M | 0.8% |
| 31 | OKUROnkure Therapeutics Inc | 1.9M | $8.8M | 0.8% |
| 32 | OLMAOlema Pharmaceuticals Inc | 671,843 | $8.4M | 0.8% |
| 33 | MNPRMonopar Therapeutics Inc | 90,500 | $8.4M | 0.8% |
| 34 | AURAAura Biosciences Inc | 1.2M | $8.3M | 0.8% |
| 35 | SRZNSurrozen Inc | 260,000 | $6.7M | 0.6% |
| 36 | ALXOALX Oncology Holdings Inc | 3.2M | $6.6M | 0.6% |
| 37 | MSLESatellos Bioscience Inc | 813,666 | $6.3M | 0.6% |
| 38 | AVTXAvalo Therapeutics Inc | 275,000 | $5.1M | 0.5% |
| 39 | PEPGPepgen Inc | 2.3M | $4.2M | 0.4% |
| 40 | VALNValneva SE | 763,199 | $4.0M | 0.4% |
| 41 | SERASera Prognostics Inc | 1.7M | $3.0M | 0.3% |
| 42 | UNCYUnicycive Therapeutics | 550,000 | $2.6M | 0.2% |
| 43 | TILInstil Bio Inc | 292,743 | $2.3M | 0.2% |
| 44 | INMInMed Pharmaceuticals Inc | 798,377 | $1.2M | 0.1% |
| 45 | BOLTBolt Biotherapeutics Inc | 72,414 | $278,794 | 0% |
| 46 | KTTAPasithea Therapeutics Corp | 465,471 | $239,904 | 0% |
| 47 | DTILPrecision Biosciences Inc | 4,675 | $36,746 | 0% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.